Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Other Non-Current Assets (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Other Non-Current Assets for 4 consecutive years, with $12815.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 34.87% to $12815.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $12815.0, a 34.87% decrease, with the full-year FY2024 number at $19676.0, up 22.52% from a year prior.
  • Other Non-Current Assets was $12815.0 for Q3 2025 at bioAffinity Technologies, roughly flat from $12814.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $19676.0 in Q3 2024 to a low of $6000.0 in Q3 2022.
  • A 4-year average of $13719.3 and a median of $16060.0 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 184.32% in 2024, then plummeted 34.87% in 2025.
  • bioAffinity Technologies' Other Non-Current Assets stood at $6000.0 in 2022, then skyrocketed by 167.67% to $16060.0 in 2023, then grew by 22.52% to $19676.0 in 2024, then tumbled by 34.87% to $12815.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Other Non-Current Assets are $12815.0 (Q3 2025), $12814.0 (Q2 2025), and $19675.0 (Q1 2025).